Understand the source comparison
Peptides for Wound Healing: Type Comparison
GHK-Cu (copper peptide) Integrin receptor binding → MMP-2 upregulation + TIMP activation Randomized controlled trials in humans (Level 1) Inflammatory through proliferative 1–2% topical cream or serum Strongest evidence base for chronic wounds; FDA-recognized
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHK-Cu (copper peptide)
- Integrin receptor binding → MMP-2 upregulation + TIMP activation
- Randomized controlled trials in humans (Level 1)
- Inflammatory through proliferative
- 1–2% topical cream or serum
- Strongest evidence base for chronic wounds; FDA-recognized as cosmetic ingredient but used off-label clinically
- TB-500 (thymosin beta-4 fragment)
- Actin monomer sequestration → enhanced cell migration
- Animal models and case reports (Level 3)
- Early proliferative (days 3–7)
- 500–750 mcg per wound site
- Promising preclinical data; human trials needed; requires threshold dosing
- BPC-157 (gastric peptide derivative)
- VEGFR2 activation → angiogenesis and capillary sprouting
- Small case series and animal models (Level 3)
- Mid-proliferative (days 5–14)
- 1 mg/mL topical solution
- Mechanistically sound; limited human data; regulatory status unclear in most jurisdictions
- Epithalon (tetrapeptide)
- Telomerase activation (theoretical)
- In vitro only; no wound healing trials
- Not validated for wound care
- N/A
- No clinical wound healing evidence; marketed for anti-aging without substantiation